Sanofi: Carcinoma, Medullary trials

The registry lists 10 Carcinoma, Medullary studies with Sanofi as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 1 2Phase 2 2Phase 3 2Phase 4 1No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid CarcinomaCompletedNCT01661179Phase 1/2Results posted
• To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid CancerCompletedNCT01496313Phase 4Results posted
• Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib TreatmentCompletedNCT01298323Phase 3Results posted
• An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid CancerCompletedNCT00410761Phase 3Results posted
• A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid CancerCompletedNCT00358956Phase 2Results posted
• Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTCApproved for marketingNCT04204928
• CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical PracticeCompletedNCT02109250
• Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid CancerCompletedNCT01945762
• Vandetanib Risk Minimisation EffectivenessCompletedNCT01757470
• Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of VandetanibCompletedNCT01539655Phase 1